Literature DB >> 7728021

Promoting cost effective prescribing.

N Freemantle, D Henry, A Maynard, G Torrance.   

Abstract

Mesh:

Year:  1995        PMID: 7728021      PMCID: PMC2549355          DOI: 10.1136/bmj.310.6985.955

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  11 in total

1.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction.

Authors:  E M Antman; J Lau; B Kupelnick; F Mosteller; T C Chalmers
Journal:  JAMA       Date:  1992-07-08       Impact factor: 56.272

2.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination.

Authors:  S H Woolf; R N Battista; G M Anderson; A G Logan; E Wang
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis.

Authors:  P C Gøtzsche
Journal:  Control Clin Trials       Date:  1989-03

5.  The cost-benefit approach.

Authors:  A Williams
Journal:  Br Med Bull       Date:  1974-09       Impact factor: 4.291

6.  Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.

Authors:  N Freemantle; A House; F Song; J M Mason; T A Sheldon
Journal:  BMJ       Date:  1994-07-23

7.  The pharmaceutical industry and health reform: lessons from Europe.

Authors:  J Hutton; M Borowitz; I Oleksy; B R Luce
Journal:  Health Aff (Millwood)       Date:  1994       Impact factor: 6.301

8.  Something rotten in the state of clinical and economic evaluations?

Authors:  N Freemantle; A Maynard
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046

9.  The scandal of poor medical research.

Authors:  D G Altman
Journal:  BMJ       Date:  1994-01-29

10.  What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.

Authors:  B Jönsson; P E Bebbington
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

View more
  15 in total

Review 1.  Drug rationing in the UK National Health Service. Current status and future prospects.

Authors:  T Walley; A Haycox; S Barton
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

2.  Publication bias in clinical trials and economic analyses.

Authors:  N Freemantle; J Mason
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

3.  An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.

Authors:  S Hummel; J Piercy; R Wright; A Davie; A Bagust; J McMurray
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

4.  The UK pharmaceutical market. An overview.

Authors:  A Towse
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 5.  Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.

Authors:  M Pringle
Journal:  BMJ       Date:  1998-10-24

6.  Sharing resources to create a district drug formulary: a countywide controlled trial.

Authors:  I Hill-Smith
Journal:  Br J Gen Pract       Date:  1996-05       Impact factor: 5.386

7.  Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.

Authors:  K Bloor; A Maynard; N Freemantle
Journal:  BMJ       Date:  1996-07-06

8.  The ethics of complementary medicine.

Authors:  E Ernst
Journal:  J Med Ethics       Date:  1996-08       Impact factor: 2.903

9.  An analysis of the influence of framework aspects on the study design of health economic modeling evaluations.

Authors:  Sebastian Gurtner
Journal:  Eur J Health Econ       Date:  2011-11-05

10.  Promoting cost effective prescribing. More trials from general practice are needed.

Authors:  D M Tracey
Journal:  BMJ       Date:  1995-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.